(easy) Top 300 Drug Quiz 4 - Drugs #1-35 (Brand + Generic + Class + FDA)

amoxicillin FDA indications:

a___ o___ media

___ respiratory tract infection

p___itis

t____itis

s___ p___itis

infection of e___, n___, t___, s___ ,s___ tissue, or ___ system

H. p___ GI tract infection

acute otitis media

lower respiratory tract infection

pharyngitis

tonsilitis

streptococcal pharyngitis

infection of ear, nose, throat, skin, subcutaneous tissue, or genitourinary system

H. pylori GI tract infection

amoxicillin/clavulanate FDA indications:

a___ o___ media

c___-acquired p___

l___ respiratory tract infection

s___, infection of s___ or s___ tissue, infectious disease of g___ system

u___ tract infection, acute c___itis

u___ tract infection, p___itis

acute otitis media

community-acquired pneumonia

lower respiratory tract infection

sinusitis, infection of skin or subcutaneous tissue, infectious disease of genitourinary system

urinary tract infection, acute cystitis

urinary tract infection, pyelonephritis

azelastine FDA indications:

p___ allergic r___itis

s___ allergic r___itis

v___ r___itis

perennial allergic rhinitis

seasonal allergic rhinitis

vasomotor rhinitis

azithromycin FDA indications:

a___ infective exacerbation of C___, s___ or t___ infection

b___ s___itis

c___, n___ c___itis, n___ u___itis

c___-acquired p___

s___ transmitted infections

s___ p___

acute infective exacerbation of COPD, skin or tissue infection

bacterial sinusitis

chancroid, nongonococcal cervicitis, nongonococcal urethritis

community-acquired pneumonia

sexually transmitted infections

streptococcal pharyngitis

benazepril FDA indications:

h___

hypertension

benzonatate FDA indications:

c___

cough

canaglifozin FDA indications:

d___ m___, type ___

diabetes mellitus, type 2

chlorthalidone FDA indications:

h___

hypertension

clarithromycin FDA indications:

a___ infective exacerbation of b___

c___-acquired p___, s___ infection, s___itis, p___itis

d___ infection due to M. a___-intracellulare group, p___-HIV infection, p___ prevention and treatment

H. p___ GI tract infection

s___ p___itis (group ___)

C___, a___ exacerbation

acute infective exacerbation of bronchitis

community-acquired pneumonia, skin infection, sinusitis, pharyngitis

disseminated infection due to M. avium-intracellulare group, prophylaxis-HIV infection, primary prevention and treatment

H. pylori GI tract infection

streptococcal pharyngitis (group A)

COPD, acute exacerbation

dapagliflozin FDA indications:

d___ m___, type ___

h___ failure with reduced e___ f___

diabetes mellitus, type 2

heart failure with reduced ejection fraction

diptheria toxoid FDA indications:

prevention of d___

prevention of diptheria

dulaglutide FDA indications:

d___ m___, type ___

diabetes mellitus, type 2

enalapril FDA indications:

h___ failure

h___

k___ disease, non___

heart failure

hypertension

kidney disease, nondiabetic

epinephrine auto-injector FDA indications:

emergency treatment of a___ a___ due to ___ reactions

emergency treatment of acute anaphylaxis due to allergic reactions

exenatide FDA indications:

d___ m___, type ___

diabetes mellitus, type 2

ezetimibe FDA indications:

f___ hyper___-h___, with a___ or s___

mixed hyper___

p___ hyper___

familial hypercholesterolemia-homozygous, with atorvastatin or simvastatin

mixed hyperlipidemia

primary hypercholesterolemia

fenofibrate FDA indications:

hyper___, primary hyper___, or mixed d___

hyper___, F___ types ___ and ___ hyper___

hypercholesterolemia primary hypercholesterolemia, or mixed dyslipidemia

hypertriglyceridemia, Frederickson types 4 and 5 hyperlipidemia

fidaxomicin FDA indications:

C. d___ infection

C. difficile infection

fosinopril FDA indications:

h___ failure

h___

heart failure, hypertension

gemfibrozil FDA indications:

c___ a___; p___-f___ combined hyper___

f___ type ___ hyper____-F___ type ___ hyper___

coronary arteriosclerosis; prophylaxis-familial combined hyperlipidemia

familial type V hyperlipoproteinemia-Fredrickson type IV hyperlipoproteinemia

haemophilus influenzae, type B vaccine FDA indications:

prevention of i___ H. i___ type ___ infection

prevention of invasive H. influenzae type B infection

hydralazine FDA indications:

h___

hypertension

hydrochlorothiazide FDA indications:

e___; a___

h___

edema; adjunct

hypertension

liraglutide FDA indications:

d___ m___, type ___

c___ w___ management

diabetes mellitus, type 2

chronic weight management

lisinopril FDA indications:

___-segment e___ MI

h___ failure with r___ e___ fraction

h___

ST-segment ejection MI

heart failure with reduced ejection fraction

hypertension

meclizine FDA indications:

m___ sickness

v___

motion sickenss

vertigo

meningococcal vaccine FDA indications:

prevention of i___ m___ disease caused by serotypes ___,___,___,___-135

prevention of i___ m___ disease caused by serotype ____

prevention of invasive meningococcal disease caused by serotypes A, C, Y, W-135

prevention of invasive meningococcal disease caused by serotypes B

niacin FDA indications:

c___ a___, hyper___

d___

A___, secondary p___

coronary arteriosclerosis, hypercholesterolemia

dyslipidemia

AMI, secondary prophylaxis

oseltamivir FDA indications:

i___ virus types ___ and ___, treatment

i___ virus types ___ and ___, p___

influenza virus types A and B, treatment

influenza virus types A and B, prophylaxis

penicillin FDA indications:

b___ e___itis, p___ in patients with c___ h___ disease or r___/acquired v___ h___ disease

o___itis media, m___-m____, p___

s___ p___

e___, ___ infection or s___-d___ therapy

bacterial endocarditis, prophylaxis in patients with congenital heart disease or rheumatic/acquired valvular heart disease

otitis media, mild-moderate, pneumococcal

streptococcal pharyngitis

erysipelas, mild infection or step-down therapy

pertussis vaccine FDA indications:

prevention of p___

prevention of pertussis

pneumococcal vaccine FDA indications:

prevention of i___ p___ disease

prevention of invasive pneumococcal disease

promethazine FDA indications:

m___ sickeness

a___

n___ and v___

motion sickness

allergy

nausea and vomiting

spironolactone FDA indications:

h___ failure, N___ class ___-___

e___ associated with h___ failure

n___ syndrome

h___

h___

heart failure, NYHA class III-IV

edema associated with heart failure

nephrotic syndrome

hypertension

hypokalemia

triamterene/hydrochlorothiazide FDA indications:

e___

h___

edema

hypertension